Bavarian Nordic starts Phase I/II trials with HIV vaccine MVA-BN

|

LONDON (AFX) - Bavarian Nordic AS said it has started a Phase I and a Phase I/II clinical study in Europe with MVA-BN polytope vaccine against HIV.

The vaccine was recently released from the company's facility in Berlin for use in clinical trials.

Results from both studies are expected in the second half of 2007.

MVA-BN polytope is the second of the company's three vaccine candidates to enter clinical trials.

source